Consolidated Statements of Stockholders' Deficit - USD ($) shares in Thousands, $ in Thousands		Total	Common Stock		Additional Paid-In Capital	Accumulated Other Comprehensive Loss		Retained Earnings	Treasury Stock	Non-redeemable Noncontrolling Interests in Subsidiaries
Beginning balance (in shares) at Dec. 26, 2021			35,797
Beginning balance at Dec. 26, 2021		$ (172,458)	$ 490		$ 445,126	$ (9,971)	[1]	$ 183,157	$ (806,472)	$ 15,212
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[2]	68,775						67,772		1,003
Other comprehensive income (loss), net of tax		(164)				(164)	[1]
Dividends on common stock		$ (54,767)			210			(54,977)
Exercise of stock options (in shares)		82	82
Exercise of stock options		$ 4,036	$ 1		4,035
Acquisition of Company common stock (in shares)		(1,343)	(1,343)
Acquisition of Company common stock		$ (125,000)							(125,000)
Stock-based compensation expense		18,388			18,388
Issuance of restricted stock (in shares)			285
Issuance of restricted stock		0			(8,443)				8,443
Tax effect of restricted stock awards (in shares)			(94)
Tax effect of restricted stock awards		(9,546)			(9,546)
Distributions to noncontrolling interests		(486)								(486)
Other (in shares)			9
Other		558			59			(96)	595
Ending balance (in shares) at Dec. 25, 2022			34,736
Ending balance at Dec. 25, 2022		(270,664)	$ 491		449,829	(10,135)	[1],[3]	195,856	(922,434)	15,729
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[4]	82,601						82,098		503
Other comprehensive income (loss), net of tax		2,332				2,332	[3]
Dividends on common stock		$ (58,806)			121			(58,927)
Exercise of stock options (in shares)		43	43
Exercise of stock options		$ 2,252	$ 1		2,251
Acquisition of Company common stock (in shares)		(2,523)	(2,523)	[5]
Acquisition of Company common stock	[5]	$ (212,444)							(212,444)
Stock-based compensation expense		17,924			17,924
Issuance of restricted stock (in shares)			240
Issuance of restricted stock		0			(7,149)				7,149
Tax effect of restricted stock awards (in shares)			(77)
Tax effect of restricted stock awards		(6,416)			(6,416)
Distributions to noncontrolling interests		(756)								(756)
Other (in shares)			69
Other		$ 361			(4,270)				4,631
Ending balance (in shares) at Dec. 31, 2023		32,500	32,488
Ending balance at Dec. 31, 2023		$ (443,616)	$ 492		452,290	(7,803)	[3],[6]	219,027	(1,123,098)	15,476
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[7]	83,923						83,486		437
Other comprehensive income (loss), net of tax		(653)				(653)	[6]
Dividends on common stock		$ (60,672)			124			(60,796)
Exercise of stock options (in shares)		23	23
Exercise of stock options		$ 1,055	$ 1		1,054
Acquisition of Company common stock (in shares)		0
Stock-based compensation expense		$ 9,590			9,590
Issuance of restricted stock (in shares)			177
Issuance of restricted stock		0			(6,539)				6,539
Tax effect of restricted stock awards (in shares)			(54)
Tax effect of restricted stock awards		(3,619)			(3,619)
Distributions to noncontrolling interests		(603)								(603)
Other (in shares)			12
Other		$ 379			(451)				830
Ending balance (in shares) at Dec. 29, 2024		32,600	32,646
Ending balance at Dec. 29, 2024		$ (414,216)	$ 493		$ 452,449	$ (8,456)	[6]	$ 241,717	$ (1,115,729)	$ 15,310

[1] At December 25, 2022, the accumulated other comprehensive loss of $10,135 was comprised of net unrealized foreign currency translation loss of $8,696 and a net unrealized loss on the interest rate swap agreements of $1,439.

[2] Net income for the year ended December 25, 2022 excludes $574 allocable to the redeemable noncontrolling interests for our joint venture arrangements.

[3] At December 31, 2023, the accumulated other comprehensive loss of $7,803 was comprised of net unrealized foreign currency translation loss of $7,490 and a net unrealized loss on the interest rate swap agreements of $314.

[4] Net income for the year ended December 31, 2023 excludes $198 allocable to the redeemable noncontrolling interests for our joint venture arrangements.

[5] Acquisition of Company common stock for the year ended December 31, 2023 includes $2,804 of transaction costs directly attributable to share repurchases, including a 1% excise tax incurred under the Inflation Reduction Act of 2022.

[6] At December 29, 2024, the accumulated other comprehensive loss of $8,456 was comprised of net unrealized foreign currency translation loss of $8,332 and a net unrealized loss on the interest rate swap agreements of $124.

[7] Net income for the year ended December 29, 2024 excludes $274 allocable to the redeemable noncontrolling interests for our joint venture arrangements.